Lest we forget. Dr. Coley’s advances were buried for well over half a century. Later, so were Ruth and John Graham’s lysate vaccine work for cervical cancer.
When we look back years from now regarding how doctors Liau, Prins (& UCLA researchers), along with NWBO’s Boynton, Bosch and CEO Powers kept DCVax technology from disappearing off the radar, I think some things will start to make more sense.
From starting with the safest, least aggressive, least threatening and broadest spectrum DC therapy, to Dr. Liau’s tireless continuing educational grand rounds and global conference appearances, to Dr. Bosch’s nearly annual updates at ASCO’s Industry Expert Theater, linking UCLA’s/NWBO’s /Advent’s/Flaskwork’s research breakthroughs/developments, and his unending patent expansion, to Dr. Prins (and other UCLA researchers), continually optimizing and documenting the foundational scientific basis for DCVax, to Linda Powers working with regulators and establishing a path to manufacturing scale up with Cognate, Advent and Flaskworks; these giants, plus many others, worked all this time to keep DCVax technology ** from suffering Dr. Coley’s and Doctors’ Graham’s works’ back-burner fate.
Watching history in real time, as an investor, is a roller coaster ride and a lesson in patience, but it has also been quite something to witness these pioneers, day in and day out, grabbing their lunch boxes and working to bring the world a beginning to the end of cancer.
(** Not to mention the future combination and DC advancements NWBO/UCLA are developing.)
